FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Исследования/Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.
Назад в Научную Библиотеку
tirzepatideGIP receptor agonistGLP-1 receptor agonist

Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.

May 17, 2026
Share

Исходная статья

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Rosenstock Julio et al.Lancet (London, England)2021
Развивающиеся Исследования

Основано на развивающихся исследованиях. Эти выводы обещающи, но требуют дальнейшей проверки.

О данном анализе

Эта статья разбивает выводы из исходной статьи выше на доступный язык для сообщества исследований Peptide. Наша цель — подчеркнуть то, что наиболее важно — практические последствия, надежность доказательств и то, что это означает для текущих исследований.

Novel Dual GIP and GLP-1 Receptor Agonist Shows Promise in Type 2 Diabetes Management

Published: May 17, 2026 | Source: Lancet (London, England) (2021) | Category: tirzepatide, GIP receptor agonist, GLP-1 receptor agonist

Overview

A recent study published in the Lancet has shown that a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist called tirzepatide can significantly improve glycemic control and body weight in patients with type 2 diabetes who are not adequately managed by diet and exercise alone. This research highlights the potential of this new class of drugs for managing a condition that affects millions globally.

Study Background

Type 2 diabetes is a chronic illness characterized by high blood sugar levels due to insulin resistance or insufficient insulin production. Despite advancements in treatment, many patients struggle to achieve optimal glycemic control with existing therapies. The development of tirzepatide aims to address this gap by targeting both GIP and GLP-1 receptors, which are involved in glucose regulation and weight management.

What the Research Found

The SURPASS-1 trial was a 40-week, double-blind, randomized, placebo-controlled phase 3 study conducted across multiple countries. Participants were adults with type 2 diabetes inadequately controlled by diet and exercise alone who had not previously used injectable diabetes therapies. They were randomly assigned to receive once-weekly doses of tirzepatide (5 mg, 10 mg, or 15 mg) or placebo.

The primary outcome was the mean change in glycated hemoglobin (HbA1c), a measure of long-term blood sugar control. The study found that all three doses of tirzepatide led to significant reductions in HbA1c compared to placebo. Additionally, participants treated with tirzepatide experienced substantial weight loss and showed no increased risk of hypoglycaemia.

What This Means for Peptide Users

The results suggest that tirzepatide could be a promising new option for patients who have not responded well to traditional diabetes management strategies. Its dual mechanism of action targeting both GIP and GLP-1 receptors may offer enhanced efficacy in improving glycemic control and body weight, which are critical factors in managing type 2 diabetes.

Limitations and Caveats

While the study demonstrated significant benefits with tirzepatide, it had several limitations. The trial's relatively short duration of 40 weeks means that long-term safety and efficacy remain uncertain. Additionally, the exclusion of patients already on injectable therapies limits the generalizability of these findings to a broader patient population.

How This Compares to Previous Research

Previous studies have focused primarily on GLP-1 receptor agonists alone for type 2 diabetes management. The introduction of tirzepatide represents an advancement by targeting both GIP and GLP-1 receptors, potentially offering superior therapeutic effects compared to single-receptor agonists.

Our Analysis

The SURPASS-1 trial provides compelling evidence for the efficacy and safety profile of tirzepatide as a novel dual receptor agonist in type 2 diabetes management. However, further research is needed to confirm its long-term benefits and assess its suitability across diverse patient populations, including those already on injectable therapies.

Key Takeaways

  • Efficacy: Tirzepatide showed significant improvements in glycemic control and body weight compared to placebo.
  • Safety: The drug demonstrated a safety profile consistent with GLP-1 receptor agonists without increased hypoglycaemia risk.
  • Limitations: Short study duration and exclusion of patients on injectable therapies limit broader applicability.

Original Source

Citation: Rosenstock Julio, Wysham Carol, Frías Juan P et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.. Lancet (London, England). DOI: 10.1016/S0140-6736(21)01324-6

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Примечание Редактора

Этот анализ был подготовлен командой исследований Peptide Contacts. Мы призываем читателей проверить полный исходный источник полная методология и данные. Исходное издание доступно на PubMed.

Связанные Исследования

Comments

Sign in to join the discussion

Этот анализ сгенерирован на основе рецензированных исследований для образовательных целей только. Это не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед использованием каких-либо терапий на основе Peptide.